In:
Cardiovascular & Hematological Disorders-Drug Targets, Bentham Science Publishers Ltd., Vol. 23, No. 1 ( 2023-03), p. 50-63
Abstract:
The study aimed to assess the antihyperglycemic and antidyslipidemic activities of
Artemisia mesatlantica. Background: Artemisia mesatlantica is an endemic plant of Morocco used in traditional medicine
as an alternative treatment for diabetes. Objective: The study was designed to examine the antihyperglycemic and antidyslipidemicability of
aqueous extract of Artemisia mesatlantica (AMAE) in experimental animal models. Methods: The effect of the single and repeated oral administration (7 days of treatment) of AMAE
(60 mg/kg) on blood glucose and lipid profile were assessed in normal and streptozotocin-induced diabetic rats. Furthermore, to confirm the antidyslipidemic effect of Artemisia mesatlantica, a model
of hyperlipidemia induced by tyloxapol (Triton WR-1339) in rats was used. Results: The AMAE (60 mg/kg) was able to significantly reduce glycaemia, improve lipid profile
and increase hepatic glycogen content in STZ-induced diabetic rats. In addition, pretreatment of rats for 7 consecutive days with an aqueous extract of Artemisia mesatlantica (600 mg/kg) prior to tyloxapol
injection prevented increases in plasma levels of total cholesterol, triglycerides and LDL-c. Conclusion: From these observed results, it can be deduced that Artemisia mesatlantica possesses
remarkable antidiabetic and antihyperlipidemic properties.
Type of Medium:
Online Resource
ISSN:
1871-529X
DOI:
10.2174/1871529X23666230803113616
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2023
SSG:
15,3
Permalink
